| Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes B Zinman, C Wanner, JM Lachin, D Fitchett, E Bluhmki, S Hantel, ... New england journal of medicine 373 (22), 2117-2128, 2015 | 15068 | 2015 |
| Liraglutide and cardiovascular outcomes in type 2 diabetes SP Marso, GH Daniels, K Brown-Frandsen, P Kristensen, JFE Mann, ... New England Journal of Medicine 375 (4), 311-322, 2016 | 8841 | 2016 |
| Canagliflozin and renal outcomes in type 2 diabetes and nephropathy V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ... New England journal of medicine 380 (24), 2295-2306, 2019 | 6837 | 2019 |
| Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes … DM Nathan, JB Buse, MB Davidson, E Ferrannini, RR Holman, R Sherwin, ... Diabetes care 32 (1), 193-203, 2009 | 5016 | 2009 |
| Empagliflozin and progression of kidney disease in type 2 diabetes C Wanner, SE Inzucchi, JM Lachin, D Fitchett, M von Eynatten, ... New England Journal of Medicine 375 (4), 323-334, 2016 | 4591 | 2016 |
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy SE Kahn, SM Haffner, MA Heise, WH Herman, RR Holman, NP Jones, ... New England Journal of Medicine 355 (23), 2427-2443, 2006 | 4252 | 2006 |
| Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals HC Gerstein, JFE Mann, Q Yi, B Zinman, SF Dinneen, B Hoogwerf, ... Jama 286 (4), 421-426, 2001 | 3412 | 2001 |
| Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes RR Holman, MA Bethel, RJ Mentz, VP Thompson, Y Lokhnygina, JB Buse, ... New England Journal of Medicine 377 (13), 1228-1239, 2017 | 2462 | 2017 |
| Impaired fasting glucose and impaired glucose tolerance: implications for care DM Nathan, MB Davidson, RA DeFronzo, RJ Heine, RR Henry, R Pratley, ... Diabetes care 30 (3), 753-759, 2007 | 2267 | 2007 |
| Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association … DM Nathan, JB Buse, MB Davidson, RJ Heine, RR Holman, R Sherwin, ... Diabetes care 29 (8), 1963-1972, 2006 | 2124 | 2006 |
| Liraglutide and renal outcomes in type 2 diabetes JFE Mann, DD Ørsted, K Brown-Frandsen, SP Marso, NR Poulter, ... New England Journal of Medicine 377 (9), 839-848, 2017 | 1504 | 2017 |
| Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies TA Ciulla, AG Amador, B Zinman Diabetes care 26 (9), 2653-2664, 2003 | 1335 | 2003 |
| Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial J Rosenstock, V Perkovic, OE Johansen, ME Cooper, SE Kahn, N Marx, ... Jama 321 (1), 69-79, 2019 | 1310 | 2019 |
| Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis CK Kramer, B Zinman, R Retnakaran Annals of internal medicine 159 (11), 758-769, 2013 | 1307 | 2013 |
| Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial D Fitchett, B Zinman, C Wanner, JM Lachin, S Hantel, A Salsali, ... European heart journal 37 (19), 1526-1534, 2016 | 1195 | 2016 |
| Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+ TZD) B Zinman, J Gerich, JB Buse, A Lewin, S Schwartz, P Raskin, PM Hale, ... Diabetes care 32 (7), 1224-1230, 2009 | 1070 | 2009 |
| Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American … DM Nathan, JB Buse, MB Davidson, E Ferrannini, RR Holman, R Sherwin, ... Diabetologia 52 (1), 17-30, 2009 | 1050 | 2009 |
| Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association SD De Ferranti, IH De Boer, V Fonseca, CS Fox, SH Golden, CJ Lavie, ... Circulation 130 (13), 1110-1130, 2014 | 1006 | 2014 |
| Renal and retinal effects of enalapril and losartan in type 1 diabetes M Mauer, B Zinman, R Gardiner, S Suissa, A Sinaiko, T Strand, ... New England Journal of Medicine 361 (1), 40-51, 2009 | 985 | 2009 |
| Simple screening tests for peripheral neuropathy in the diabetes clinic BA Perkins, D Olaleye, B Zinman, V Bril Diabetes care 24 (2), 250-256, 2001 | 960 | 2001 |
